Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma
Recruiting now · Not applicable
Conditions studied: Klatskin Tumor
In brief
The objective of this study is to evaluate the efficacy of stereotactic body radiation therapy (SBRT) as additional treatment after standard chemotherapy regarding tumor local control, toxicity, progression-free survival (PFS), overall survival and quality of life. In addition, the objective is to explore the value of immunodynamics in peripheral blood for predicting PFS in patients undergoing chemotherapy.
Key facts
- Study ID
- NCT06493734
- Run by
- Erasmus Medical Center
- People needed
- 30
- Starts
- 2024-07-01
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2025-07-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University Medical Center Utrecht — Utrecht, Utrecht, Netherlands (enrolling)
- University Medical Center Groningen — Groningen, Provincie Groningen, Netherlands (enrolling)
- Erasmus MC — Rotterdam, South Holland, Netherlands (enrolling)
- Radboud University Medical Center — Nijmegen, Gelderland, Netherlands (enrolling)
- Maastricht University Medical Center+ / Maastro Clinic Maastricht — Maastricht, Limburg, Netherlands (enrolling)
- Amsterdam University Medical Center — Amsterdam, North Holland, Netherlands (enrolling)
- University Hospital Brussels / Jules Bordet Institute — Brussels, Brussels Capital, Belgium
- Antwerp University Hospital / Sint-Augustinus Gasthuiszusters — Wilrijk, Antwerp, Belgium
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.